(0.05%) 5 520.00 points
(0.10%) 39 884 points
(0.16%) 19 782 points
(0.01%) $81.64
(0.46%) $2.82
(-0.34%) $2 336.40
(-0.05%) $29.51
(0.27%) $1 004.50
(0.02%) $0.932
(0.01%) $10.53
(0.01%) $0.788
(-0.57%) $87.50
-3.84% $ 0.673
Live Chart Being Loaded With Signals
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors...
Stats | |
---|---|
Dzisiejszy wolumen | 27 310 |
Średni wolumen | 45 808 |
Kapitalizacja rynkowa | 10.78M |
EPS | $-0.110 ( Q1 | 2024-05-15 ) |
Następna data zysków | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0200 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0150 (2.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-06 | Weis Holger | Buy | 19 200 | Employee Stock Option (right to buy) |
2024-06-06 | Weis Holger | Buy | 4 524 | Employee Stock Option (right to buy) |
2024-06-06 | Vieser Jaime | Buy | 12 800 | Employee Stock Option (right to buy) |
2024-06-06 | Postma Robert W | Buy | 12 800 | Employee Stock Option (right to buy) |
2024-06-06 | Hofmeister Robert | Buy | 12 800 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
96.63 |
Last 87 transactions |
Buy: 15 616 124 | Sell: 1 296 896 |
Wolumen Korelacja
Alaunos Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
OMEX | 0.832 |
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alaunos Therapeutics, Korelacja - Waluta/Towar
Alaunos Therapeutics, Finanse
Annual | 2023 |
Przychody: | $5 000.00 |
Zysk brutto: | $-2.31M (-46 200.00 %) |
EPS: | $-2.20 |
FY | 2023 |
Przychody: | $5 000.00 |
Zysk brutto: | $-2.31M (-46 200.00 %) |
EPS: | $-2.20 |
FY | 2022 |
Przychody: | $2.92M |
Zysk brutto: | $163 000 (5.58 %) |
EPS: | $-2.60 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Alaunos Therapeutics,
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej